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Introduction. Pathological left ventricular (LV) remodeling in children with metabolic 
syndrome (MS) is associated with a significant increase in cardiometabolic risk. However, 
data regarding the prevalence of LV remodeling patterns in children with MS are limited. 
Material and methods. An observational analytical cohort study was conducted on 145 
children. The diagnosis of MS was established according to the International Diabetes 
Federation (IDF) criteria. We analyzed the echocardiography, as well as clinical and pa-
raclinical data. Participants were distributed, depending on LV mass index and relative 
wall thickness into four LV geometric patterns as recommended by American and Euro-
pean Society of Echocardiography: normal geometry, concentric left ventricular remo-
deling (cLVR), concentric left ventricular hypertrophy (cLVH), and eccentric left ventricu-
lar hypertrophy (eLVH). 
Results. The pathological remodeling patterns were distributed as follows: 62.1% (n=90) 
participants showed a normal LV geometry pattern, 27.6% (n=40) – cLVH, 5.5% (n=8) – 
cLVR and 4.8% (n=7) – eLVH. In terms of presence/absence of MS, 54.7% (n=29) partici-
pants from the research group showed a normal LV geometry pattern, 32.1% (n=17) – 
cLVH, 5.7% (n=3) – cLVR and 7.5% (n=4) – eLVH, whereas 66.3% (n=61) participants 
from the control group presented normal LV geometric appearance, 25% (n=23) – cLVH, 
5.4% (n=5) – cLVR and 3.3% (n=3) – eLVR (χ2=0.52; p>0.05).  
Conclusions. Concentric left ventricular hypertrophy was the commonest LV geometric 
pattern among the subjects with metabolic syndrome. Concentric left ventricular remo-
deling and eccentric left ventricular hypertrophy were rare among the study population.  
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MODELE DE REMODELARE VENTRICULARĂ STÂNGĂ LA COPIII CU SINDROM      
METABOLIC  
Introducere. Remodelarea patologică a ventriculului stâng (VS) la copiii cu sindrom 
metabolic (SM) este asociată cu o creștere semnificativă a riscului cardiometabolic. Cu 
toate acestea, date privind prevalența paternelor de remodelare ale VS la copiii cu SM 
sunt limitate. 
Material și metode. Studiu analitic, observațional, de cohortă. Au fost incluși 145 de 
copii. Diagnosticul de SM a fost stabilit conform criteriilor Federației Internaționale de 
Diabet (FID). Am analizat datele clinice, paraclinice și ecocardiografice. Participanții au 
fost stratificați în patru tipare geometrice, folosind indicele de masă a VS și grosimea 
relativă a PPVS, așa cum recomandă Societatea Americană și Europeană de Ecocardio-
grafie: geometrie normală VS, remodelare concentrică VS (RC VS), hipertrofie concen-
trică VS (HC VS) și hipertrofie excentrică VS (HE VS). 
Rezultate. Tipurile de remodelare patologică s-au repartizat în felul următor: 62.1% 
(n=90) participanți au prezentat aspect geometric normal al VS,  la 27,6% (n=40) dintre 
ei s-a înregistrat HC VS, la 5,5% (n=8) participanți s-a atestat RC VS, iar 4,8% (n=7) din 
acest lot au prezentat HE VS. În funcție de prezența/absența SM,  în lotul de bază, 54,7% 
(n=29) participanți au prezentat aspect geometric normal, la 32,1% (n=17) a  fost  înre-
gistrată HC VS, 5.7% subiecți (n=3) au manifestat RC VS, iar 7,5% (n=4) au prezentat HE 
VS, iar în lotul de control – la 66,3% (n=61) participanți s-a atestat aspect geometric 
normal al VS, 25% (n=23) au prezentat HC VS, în 5,4% (n=5) cazuri  s-a determinat  RC 
VS, iar 3,3% (n=3) participanți au prezentat HE VS (χ2=0,52; p>0,05). 
Concluzii. Hipertrofia concentrică VS a fost cel mai frecvent model geometric al VS în 
rândul subiecților cu sindrom metabolic, iar remodelarea concentrică VS și hipertrofia 
excentrică VS au fost rar depistate în rândul populației din studiu.  
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INTRODUCTION 
Metabolic syndrome (MS) is considered a recent 
major health problem, although scientific ad-
vances and therapeutic strategies have provided 
lots of opportunities for its management. It gets 
even more important if it occurs in children since 
the therapeutic possibilities in pediatric patients 
are quite limited due to the considerable side 
effects and/or no sufficient studies so far. 
Metabolic syndrome is a pediatric pathology, 
leading to several early disorders, including car-
diovascular disease (CVD)(1), showing an in-
creased risk due to its early onset and duration. 
The prevalence rate varies between 10% and 
84%, depending on the geographical region, en-
vironment, individual demographic characteris-
tics (gender, age, race, and ethnic origin), as well 
as other criteria used for its defining (2). In 
terms of gender, most studies show a higher fre-
quency in males (3, 4), whereas the differences 
also vary depending on the age gaps, being high-
er in males than adolescent females (10.9% vs 
6.29%), subsequently being reversed in adult-
hood (18% vs 20% at the age of 20-39 years and 
42% vs 51% at the age ≤ 60 years) (5). 
Pediatric MS correlates with cardiac structural 
and geometrical changes, leading to a cardiac 
pathological remodeling, which is considered a 
substrate for developing heart failure, being also 
a strong predictor of arrhythmia, characterized 
by an impaired heart function (systolic and dia-
stolic) and an early risk of sudden death (6).  
While considering the aforementioned argu-
ments and the impact of childhood health on 
further adult health, we considered to choose the 
following research on left ventricular remodeling 
patterns in children with MS, that will contribute 
to the opening of new perspectives for identify-
ing a single and effective approach, as well as for 
preventing cardiovascular complications of this 
syndrome, based on IDF criteria adapted for 
children, to reduce the morbidity and mortality 
rates at a young age. 
 
MATERIAL AND METHODS 
The purpose of the research: to study the left ven-
tricular remodeling patterns in children with 
metabolic syndrome. 
General design and study population. The study  
project was carried out within the IMPH IMC, at 
the Department of Pediatrics of the Pediatric 
Cardiology Clinic, to which 161 children were 
admitted, aged from 10 to 17 years 11 months 
and 29 days, from both urban and rural areas, 
the patients being selected electively during the 
2016 – 2019 period. An observational analytical 
cohort study was planned to achieve the re-
search purpose. 
The research comprised several stages. The 1st 
stage included 145 children (out of 161 partici-
pants, 16 ineligible), who were selected based on 
the inclusion/exclusion criteria, and made up the 
research group according to the following crite-
ria: the age of 10 – 17 years 11 months and 29 
days (inclusive); with abdominal obesity (waist 
circumference (WC) ≥ 90th percentile (7)); the 
child’s parent or guardian consent, as well as 
children’s assent (age ≥ 14 years) on research 
participation; being a citizen of the Republic of 
Moldova; ability to effectively communicate with 
the researcher; ability to understand and follow 
the study requirements; sufficient understanding 
in signing the informed agreement and written 
assent.  
The study exclusion criteria for the patients were 
the following: secondary obesity: endocrine, ge-
netic and neurological type, having a suggestive 
clinical examination, confirmed by specialized 
examinations; secondary high blood pressure: 
renal, endocrine, neurogenic, drug - induced, etc., 
patients having a suggestive clinical examination, 
confirmed by specialized examinations; acute 
conditions, whether or not accompanied by fe-
ver, whether or not undergoing treatment; 
chronic respiratory, cardiovascular, gastrointes-
tinal, renal, neurological, endocrine, etc., disor-
ders, whether or not  undergoing  treatment;  the  
child’s parents or legal representative disagree-
ment, child’s refusal to participate in the re-
search, with a difficult ultrasound window, low 
compliance, patient’s refusal to be included in 
the study. 
The selected participants underwent a complex 
examination, which included: filling in a specific 
questionnaire (food and physical activity sur-
vey), the clinical examination on systems, labora-
tory testing for lipid status (total cholesterol 
(TCh), triglycerides (TG), high-density cholester-
ol (HDLc)), the glucose (Glu) spectrum (basal 
glucose, oral glucose tolerance test (OGTT) – 
selectively) and uric acid. 
Following the clinical and paraclinical findings, 
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the 2nd stage included the respondent’s self-
division into 2 groups, by using the criteria of MS 
according to the Consensus of the IDF adapted 
for children [1], namely: the research group (L1) 
– 53 de children with MS (including 3  – 5 crite-
ria) and control group (L0) – 92 children without 
MS (including 1 – 2 criteria). The ratio of the 
study groups was 1:2. Subsequently, subjects 
from both groups were investigated by transtho-
racic echocardiography. 
The 3rd stage included a comparative study of the 
two groups, in terms of lifestyle, symptoms, de-
mographic, anamnestic and biochemical profile, 
cardiac function and morphology, etc., as well as 
a statistical analysis of the obtained results. Prac-
tical conclusions and recommendations, based 
on the obtained results, were traced out at the 4th 
stage of the study. 
All the participants were selected and informed 
about the research stages, being enrolled only by 
personal informed consent, following a detailed 
explanation of the requirements and procedures 
of necessary investigations by discussing with 
each subject individually. All the procedures 
were performed, based on children’s parent and 
legal representative consent, as well as on writ-
ten assent of children ≥ 14 years old. They were 
not paid and have not suffered any financial 
costs for participation.  
Ethical considerations. The study complied with 
the international standards of medical ethics, 
developed by the Declaration of Helsinki, regard-
ing confidentiality and personal data protection 
of the participants. The research was approved 
by the Research Ethics Committee of State Uni-
versity of Medicine and Pharmacy Nicolae 
Testemitanu (report no. 59 of 03.06.2016). The 
resulting data were revealed only to the con-
cerned participant, the personal data of each 
subject were not used and will not be used for 
any other purpose. The study applied the follow-
ing research methods: historical, comparative, 
biostatistics ones, and others. 
Metabolic syndrome. MS was defined according 
to the IDF consensus definition of metabolic syn-
drome in children (8): WC≥90th percentile or 
adult cut-off if lower, plus any two of the follow-
ing four factors: TG≥1.7 mmol/L, HDLc<1.03 
mmol/L, BP systolic ≥130 and diastolic ≥85 
mmHg (> 95th percentile for age, height, and sex), 
Glu≥5.6 mmol/L (If≥5.6 mmol/L (or known 
T2DM) recommend an OGTT) for age group 10 – 
<16 years, and use existing IDF criteria for 
adults: central obesity (defined as WC≥94 cm for 
Europid men and ≥ 80cm for Europid women, 
with ethnicity specific values for other groups) 
plus any two of the following four factors: 
TG≥1.7mmol/L or specific treatment for high TG, 
reduced HDLc: <1.03mmol/L in males and <1.29 
mmol/L in females, or specific treatment for low 
HDLc, systolic BP≥130 mmHg or diastolic BP≥85 
mmHg or treatment of previously diagnosed 
Arterial Hypertension, and Glu≥5.6 mmol/L or 
known T2DM for age group >16 years. 
Left ventricular geometry pattern. To define the 
LV geometry pattern, we measured the myocar-
dial mass index by M-mode echocardiography 
using the Devereux formula and normalized to 
height 2,7, as well as the relative wall thickness 
(RWT) defined as LV wall thickness + septal 
thickness relative to the internal dimensions of 
the LV. The LVH was diagnosed by cutoff value 
utilized in adults (51 g/m) corresponding to the 
97.5th percentile in children (9). The LV geomet-
ric patterns (normal, eccentric or concentric LV 
hypertrophy, and concentric LV remodeling) 
were calculated according to the left ventricular 
mass index (LVMI) and RWT. All echocardio-
graphic measurements were conducted using the 
Toshiba Aplio 300, MODEL TUS-A300 Cardiac 
Ultrasound Machine, by a specialized sonog-
rapher, who was unaware of the patients’ diag-
nosis. 
Covariates. Apart from standard biochemical 
parameters to confirm the diagnosis of MS, uric 
acid level, and LDLc (TCh - HDLc - TG/5), were 
determined in every patient. All blood specimens 
were taken after an overnight fasting. Additional 
clinical evaluation included medical history, life-
style questionnaire, anthropometric measure-
ments, physical examination, etc. 
Statistical analysis. The data collected from the  
primary material were introduced into the elec-
tronic database, whereas the statistical pro-
cessing was performed using the Statistical 
Package for the Social Sciences (SPSS) version 
20. 
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RESULTS 
According to the inclusion and exclusion criteria, 
there was formed a general group, including 145 
participants, of which 36.6% (53 pts) children 
with MS (research group) and 63.4 % (92 pts) 
children with non-MS (control group). Gender 
groups were divided into 55.9% boys (81 pts) 
and 44.1% girls (64 pts) of the total number of 
enrolled children. MS was present in 39.5% (32 
pts) boys vs 32.8% (21 pts) girls, and non-MS in 
60.5% (49 pts) boys vs 67.2% (43 pts) girls 
(χ2=0.69; p>0.05).  
 
 
 
Figure 1. The participant distribution based on the number of criteria and IDF  
consensus for children (%), n=145. 
 
According to MS criteria and based on the IDF 
agreement, 24.9% (35 pts) subjects presented 3 
criteria, 11% (17 pts) – 4 criteria and 0.7% (1 
pts) – 5 criteria, whereas 25.5% (37 pts) of the 
participants presented 1 criterion, and 37.9% 
(55 pts) – 2 of the mentioned criteria (fig. 1). 
Gender distribution revealed that 24.7% (20 pts) 
boys and 25% (16 pts) girls had 3 positive crite-
ria, and 14.8% (12 pts) boys and 7.8% (5 pts) 
girls – 4-5 criteria for metabolic syndrome 
(χ2=1.77; p>0.05). 
Also, there were selected 5 factors of MS (accord-
ing to the IDF consensus, adapted for children). 
The first factor (F1) - obesity, was recorded in 
100% (145 pts) of cases in order of prevalence 
(it might be because children included in the 
study exhibited WC ≥ 90th percentile), the second 
factor (F2) found in 47.6% (69 pts) of cases, 
showed low values of HDLc and the third factor 
(F3), found in 25.5% (37 pts) of cases, which 
were defined by high TG was named the lipidic 
factor. The fourth factor (F4), recorded in 42.8% 
(62 pts) of cases with high BP values (BP systolic 
and/or BP diastolic), was called the blood pres-
sure factor, and the fifth factor (F5), reported in 
7.6% (11 pts) of cases with higher than normal 
blood Glu levels, was related to carbohydrate 
metabolism, is less prevalent. 
The assessment of pediatric MS was also per-
formed by detecting the components and their 
association. The prevalence of cases with defined 
MS was assessed using clustering patterns, which 
was estimated according to the number of crite-
ria (tab.1).  
Cluster WC+HDLc+HBP was found in 10.3% of 
cases (15 pts), WC+TG+HDLc was registered in 
8.3% (12 pts), WC+TG+HDLc+HBP – 7.6% (11 
pts), WC+TG+HBP – 5.5% (8 pts) of cases. The 
clusters WC+HDLc+Glu+HBP and WC+TG+ 
HDLc+ Glu were found to exhibit the same fre-
quency of 1.4% (2 pts), whereas WC+Glu+HBP, 
WC+TG+ Glu+HBP and CA+TG+HDL+Glu+HBP in 
0.7% (1 pts) of cases. Gender-based clustering 
showed higher rate of WC+HDL+HBP in females 
vs male 15.6% (10 pts) vs 6.2% (5 pts) (p<0.01); 
higher WC+TG+HDL cluster rate in males vs fe-
males 9.9% (8 pts) vs 6.3% (4 pts) (p<0.01); high 
rate of WC+TG+HDLc+HBP cluster in males vs 
females 9.9% (8) vs 4.7% (3 pts) (p<0.01); 
WC+TG+HBP cluster prevailing in males vs fe-
males 8.6% (7 pts) vs 1.6% (1 pt) (p<0.01). Obe-
sity cases were found to be associated with 
dyslipidemia, high BP and glycoregulation disor-
ders (similar data was found in specialized liter-
ature among adult population, whereas no data 
were recorded for pediatric population).
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Table 1. The study of metabolic syndrome components, their association, and clustering. 
  
MS, components Total (no. %) 
Gender (no. %) 
(χ2 = 27.35; p<0.01) 
  Males Females 
WC 37 (25.5%) 20 (24.7%) 17 (26.6%) 
WC+HBP 23 (15.9%) 19 (23.5%) 4 (6.3%) 
WC+Glu 4 (2.8%) 2 (2.5%) 2 (3.1%) 
WC+TG 2 (1.4%) 1 (1.2%) 1 (1.6%) 
WC+HDLc 26 (17.9%) 7 (8.6%) 19 (29.7%) 
WC+Glu+HBP 1 (0.7%)        - 1 (1.6%) 
WC+TG+HDLc 12 (8.3%) 8 (9.9%) 4 (6.3%) 
WC+HDLc+HBP 15 (10.3%) 5 (6.2%) 10 (15.6%) 
WC+TG+HBP 8 (5.5%) 7 (8.6%) 1 (1.6%) 
WC+HDLc+Glu+HBP 2 (1.4%) 1 (1.2%) 1 (1.6%) 
WC+TG+HBP+Glu 1 (0.7%) 1 (1.2%)         - 
WC+TG+HDLc+HBP 11 (7.6%) 8 (9.9%) 3 (4.7%) 
WC+TG+HDLc+Glu 2 (1.4%) 2 (2.5%)        - 
WC+TG+HDLc+Glu+HBP 1 (0.7%)       - 1 (1.6%) 
Note: The values are presented as absolute values (and percentage) for statistically significant categorical data              
p<0.01; WC – waist circumference; TG – triglyceride; HBP – high blood pressure values; Glu – glucose; HDLc – high-
density cholesterol. 
 
The results of the selective analysis of some an-
thropometric parameters. The studied groups 
were characterized by the following values 
(tab.2): 80.5±2.05 kg in the study group vs 
73.4±2.3 kg in the control group, with the statis-
tical difference (p<0.01); the height,  values were 
168.4±1.7 cm in MS group, and 161.4±1.5 cm in 
non-MS group, with a true statistical difference; 
the mean BMI index showed absolute values in 
the study group – 28.2±0.4 kg/m2, and in the 
control group 27.1±0.5 kg/m2 (p>0.05), accord-
ing to the percentiles – 94.7±0.6 vs 93.9±0.4 
(p>0.05), and according to the Z score both 
groups had the same mean value of 1.7±0.05 
(p>0.05); the mean values of WC were 94.5±1.2 
cm in the MS group and 90.5±1.07 cm in the con-
trol group (according to the percentiles, in 100% 
of WC cases ≥90th percentile), with a statistically 
significant difference (p<0.05); hip circumfer-
ence was 103.5±1.3 cm in children with MS and 
98.7±1.3 cm in those with non-MS, with a statis-
tically significant difference (p<0.05); abdominal 
index – 0.9±0.01 and the waist-to-hip-ratio was 
higher in the study vs control group 1.88±0.03 
m2 vs 1,76±0.03 m2, but showing no significant  
statistical difference (p>0.05). 
The results of the evaluation of some biochemical 
parameters. A comparative  study  between  the 
biochemical indices in children with MS vs non-
MS revealed the following mean values (tab.2): 
TG – 1.97±0.2 mmol/l, compared to 1.16±0.03 
mmol/L (p<0.001); TCh – 4.09±0.14 mmol/L, 
compared to 4.06±0.09 mmol/L (p>0.05); HDLc 
– 1.03±0.03 mmol/L vs 1.33±0.03 mmol/L 
(p<0.001); LDLc – 2.11±0.12 mmol/L vs 
2.05±0.17 mmol/L (p<0.001); LDLc/HDLc – 
2.04±0.04 mmol/L vs 1.54±0.05 mmol/L 
(p<0.001); TCh/HDLc – 3.97±0.01 mmol/L vs 
3.05±0.01 mmol/L (p>0.05); ẞ-lipoproteins 
45.15±1.78 mmol/L, compared to 46.74±1.21 
mmol/L (p>0.05) and uric acid – 315.41±10.65 
mmol/L, compared with 292.88±8.56 mmol/L 
(p>0.05). 
The results of the evaluation of the types of remo-
deling of the left ventricular myocardium (fig.2). 
The distribution of LV remodeling types was 
carried out as recommended by the American 
and European Society of Echocardiography, 
based on the mea-surements of LVMI and RWT. 
The types of pathological remodeling were dis-
tributed as follows: 62.1% (n=90) participants 
showed a normal geometry pattern of LV, 27.6% 
(n=40) – concentric LV hypertrophy, 5.5% (n=8) 
– concentric LV remodeling, and 4.8% (n=7) – 
eccentric LV hypertrophy. 
In terms of presence/absence of MS, 54.7% 
(n=29) participants from the research group 
showed a normal LV geometry pattern, 32.1% 
(n=17) – concentric LV hypertrophy, 5.7% (n=3) 
– concentric LV remodeling and 7.5% (n=4) – 
eccentric  LV  hypertrophy,  whereas  66.3%  (n= 
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61) participants from the control group present-
ed normal LV geometric appearance, 25% 
(n=23) – concentric LV hypertrophy, 5.4% (n=5) 
– concentric LV remodeling and 3.3% (n=3) – 
eccentric LV hypertrophy  (χ2=0.52; p>0.05)  
(fig. 3). 
 
Table 2. The values of some anthropometric and biochemical parameters in children 
 included within the research. 
 
Variables (M±m) MS non-MS p-value 
Weight, M±m, (kg) 80.5±2.05 73.4±2.3 <0.01 
Height, M±m, (cm) 168.4±1.7 161.4±1.5 <0.01 
BMI, M±m, (kg/m2) 28.2±0.4 27.1±0.5 SI 
BMI, M±m, (percentiles) 94.7±0.6 93.9±0.4 SI 
BMI, M±m, (Z score) 1.7±0.05 1.7±0.05 SI 
WC, M±m,(cm) 94.5±1.2 90.5±1.07 <0.05 
HC, M±m,(cm) 103.5±1.3 98.7±1.3 <0.05 
WHR, M±m, 0.9±0.01 0.9±0.01 SI 
AI, M±m, 0.6±0.01 0.6±0.01 SI 
BSA (m2) M±m, 1.88±0.03 1.76±0.03 SI 
TG (mmol/l) 1.16±0.03 1.97±0.2 <0.001 
TCh (mmol/l) 4.06±0.09 4.09±0.14 SI 
HDLc (mmol/l) 1.33±0.03 1.03±0.03 <0.001 
LDLc (mmol/l) 2.05±0.17 2.11±0.12 <0.001 
TCh/HDLc  3.05±0.01 3.97±0.01 SI 
LDLc/HDLc 1.54±0.05 2.04±0.04 <0.001 
ẞ-lipoproteins ( mmol/l) 46.74±1.21 45.15±1.78 SI 
Uric acid (mmol/l) 292.88±8.56 315.41±10.65 SI 
Note: Values are presented as mean ± standard deviation for a number of values; SI – statistically insignificant              
(p>0.05); the value of p<0.05 = considered significant; the value of p<0.001 = considered significant; BSA – body 
surface area; AI – abdominal index; WHR –waist-to-hip-ratio; HC – hip circumference; WC – waist circumference; 
BMI – body mass index; TG – triglycerides, TCh – total cholesterol, HDLc – high density cholesterol, LDLc – low densi-
ty cholesterol 
 
 
 
Figure 2. Left ventricular remodeling patterns (%). 
Note: nLV – normal LV appearance, cLVR – concentric LV remodeling; cLVH – concentric LV hypertrophy;                   
eLVH – eccentric LV hypertrophy. 
 
The gender-related distribution revealed the 
following results in boys: 63.4% (n=52) – normal 
LV geometric appearance, 24.4% (n=20) – con-
centric LV hypertrophy, 4.9% (n=4) – concentric 
LV remodeling and 7.3% (n=6) – eccentric LV 
hypertrophy and in girls: 60.3% (n=38) – normal 
 
LV geometric appearance, 31.7% (n=20) – con-
centric LV hypertrophy, 6,3% (n=4) – concentric 
LV remodeling and 1.6% (n=1) showed eccentric 
LV hypertrophy (χ2=0.34; p>0.05). 
Depending on the number of MS criteria, a nor-
mal  LV   geometry    appearance   was   found  in  
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5.5
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4.8
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25.8% (n=24) of MS children with 1 positive 
criterion, 38.7% (n=37) – 2 criteria, 24.2% 
(n=21) – 3 criteria and in 11.3% (n=8) cases with 
4-5 criteria. Concentric LV remodeling was rec-
orded in 10% (n=1) subjects with 4-5 MS crite-
ria, and in 30.0% (n=2) of cases with 1, 2 and 3 
criteria. Concentric LV hypertrophy was record-
ed in 15.2% (n=8) of MS children with 1 positive 
criterion, 27.3% (n=15) – 2 criteria, 32.6% 
(n=11) – 3 criteria and 24.9% (n=6) – 4-5 crite-
ria. Eccentric LV hypertrophy was found in 
11.7% (n=1) of MS children with 1 positive crite-
rion, 19.1% (n=2) – 2 criteria, 27.9% (n=1) – 3 
criteria and 41.3% (n=3) – 4-5 criteria (χ2=3.58; 
p>0.05) (fig. 4)  
   
 
 
 
Figure 3. Left ventricular remodeling patterns depending on the presence/absence  
of metabolic syndrome. 
Note: nLV – normal LV appearance, cLVR – concentric LV remodeling; cLVH – concentric LV hypertrophy;eLVH –
eccentric LV hypertrophy. 
 
 
Figure 4. Left ventricular remodeling patterns depending on the number of MS criteria and  
according to IFD Consensus for children.  
Note: nLV – normal LV appearance. cLVR – concentric LV remodeling; cLVH – concentric LV hypertrophy; eLVH – 
eccentric LV hypertrophy. 
 
According to MS clustering, concentric LV remo-
deling was recorded in 15% (n=1) of subjects 
with WC+TG+HBP, WC+HDLc+HBP and WC+ 
HDLc+TG+HBP clustering patterns. Eccentric LV 
hypertrophy was recorded in 14.7% (n=1) of 
participants with WC+HDLc+HBP, WC+HDLc+ 
TG+HBP+Glu and 27.9% (n=2) of subjects with 
WC+HDLc+TG+HBP cluster patterns. Concentric 
LV  hypertrophy  was  found  in  18.7%  (n=6)  of 
participants with WC+HDLc+HBP clusters, 6.1%  
(n=4) of cases with WC+TG+HBP and WC+ 
TG+HDLc+HBP and in 1.6% (n=1) – WC+TG+ 
HDLc, WC+TG+Glu+HBP, WC+TG+HDLc +Glu. 
The LV with normal geometric appearance had a 
different overall distribution, being registered in 
all clinical patterns (χ2=11.96; p>0.05). 
The risk for installing of left ventricular myocar-
dial remodeling. During the research, the risk of 
installing the LV myocardium remodeling pat-
terns  in  children  with  MS  has  also  been  de-
termined, initially being formed as "table 2x2", 
afterwards the necessary indicators were calcu-
lated and the obtained results were interpreted. 
Respectively, RR (relative risk) = 1.7 was ob-
tained, ranging between 1.7 – 2.5, which was 
considered a moderate risk. Thus, MS is a risk 
factor for the development of LV myocardium 
remodeling, whereas taking into account that  
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confidence interval (CI) does not include value 1 
(CI is between 1.3 and 4.2) it can be concluded 
that there is a positive association between these 
two.  
 
DISCUSSIONS 
MS is a clinical condition, which is associated 
with an increased risk of cardiovascular diseases 
(10). The present study investigated a well-
defined general population, aged between 10–18 
years, the prevalence of the MS and that of its 
contributors, as well as the relationship with 
non-invasively measured markers of cardiac 
involvement. 
The syndrome was found to have a considerable 
prevalence in the pediatric population, averaging 
36.6% of all subjects aged between 10-18 years, 
showing greater prevalence among boys (39.5% 
vs 32.8%), which was similar to previous studies 
(10).  
Regarding the MS-related factors, apart from 
visceral adiposity present by definition in 100% 
of cases, high TG (25.5%), high BP (42.8%), and 
low HDLc (47.6%) values were the most fre-
quently detected. 
The assessment of pediatric MS was also per-
formed by detecting the components and their 
association. The prevalence of cases with defined 
MS was assessed by using the clustering pat-
terns, being estimated according to a number of 
criteria. The clusters WC+HDLc+HBP, WC+TG+ 
HDLc, WC+TG+HDLc+HBP, WC+TG+HBP were 
the most frequently registered. Obesity cases 
were found to be associated with dyslipidemia, 
high BP, and glucose regulation disorders (simi-
lar data were found in specialized literature 
among the adult population, whereas no data 
were recorded for the pediatric population). 
In our study, MS subjects-compared to non-MS 
had significantly higher values of weight, waist 
circumference,  hip  circumference,  triglycerides,  
as well as lower levels of HDL-cholesterol. The 
anthropometric and biochemical data altogether 
are the most important features of metabolic 
syndrome in this present research. 
The analysis of cardiac remodeling types showed 
a higher incidence in pediatric subjects with 
normal LV geometric appearance – 62.1%. The 
three pathological LV remodeling subtypes (ec-
centric hypertrophy, concentric hypertrophy, 
and concentric remodeling) showed a higher 
rate for concentric LV hypertrophy – 27.6%, fol-
lowed by concentric LV remodeling type – 5.5% 
and eccentric LV hypertrophy – 4.8%, which was 
predominantly found in males, for three positive 
criteria, and within the following clusters 
WC+HDLc+HBP, WC+TG+HDLc, WC+TG+HDLc+ 
Glu, WC+TG+ HDLc+HBP, showing no statistical-
ly significant difference (p>0.05; similar data 
were found in specialized literature among the 
adult population, whereas no data were record-
ed for pediatric population). 
Finally, during the research, the potential risk of 
installing remodeling patterns of LV myocardium 
in children with MS was also estimated, after 
calculating the necessary indicators. The syn-
drome was found to be a risk factor, as well as an 
association between MS and remodeling of the 
LV myocardium, which has been identified. 
Some limitations of this study must be taken into 
account. The current study included a relatively 
small number of patients, particularly of subjects 
aged between 16-18 years, although metabolic 
syndrome is considered to have a high incidence 
rate. The main study limitation regarding the 
patients’enrollment was the fact that we aimed 
at identifying pediatric subjects with MS from 
within the Cardiology Clinic. Another reason for 
a relatively small number of participants was the 
careful selection of patients, as to obtain an op-
timal ultrasound window, for an accurate analy-
sis of the echocardiographic data. The short-term 
MS installation is another study limitation. 
 
CONCLUSIONS 
1. According to the International Diabetes Federation definition, 24.9% of the subjects presented 3 
criteria, 11% – 4 criteria and 0.7% – 5 positive criteria (25.5% – 1 criterion, and 37.9% – 2 criteria) 
for metabolic syndrome. Waist circumference ≥ 90 th percentile was recorded in 100% of cases, high 
densi ty cholesterol value <1.03 mmol/L/1.29 mmol/L – in 47.6%, triglyceride value ≥1.7 mmol/L –
in 25.5%, systolic blood pressure value ≥130 mmHg/diastolic blood pressure ≥85 mmol/L  – in 
42.8%, and glucose values ≥5.6 mmol/L – in 7.6%.  
2. The analysis of cardiac remodeling types showed a higher incidence in pediatric subjects wi th nor 
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mal left ventricular geometric appearance – 62.1%. The three pathological remodeling subtypes 
(eccentric hypertrophy, concentric hypertrophy, and concentric remodeling) showed a higher rate 
for concentric left ventricular hypertrophy – 27.6%, followed by concentric left ventricular remo-
deling type – 5.5% and eccentric left ventricular hypertrophy – 4.8%. 
3. In children aged 10-18 years, metabolic syndrome is a risk factor and has a positive association 
with the development of left ventricular myocardial remodeling (relative risk=1.7, confidence in-
terval=1.3-4.2). 
 
PRACTICAL RECOMMENDATIONS 
1. Screening of the metabolic syndrome is recommended in children with abdominal obesity, aged 10 
– 18 years in order to detect those cases, who are at risk of developing complications. 
2. Echocardiography is recommended to assess the presence of structural remodeling patterns of left 
ventricular myocardium, which will allow detecting children with metabolic syndrome and those 
who are at higher risk for developing cardiovascular complications. 
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